Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Valeo Pharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Valeo Pharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Valeo Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Valeo Pharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Valeo Pharma's earnings growth to the Canada market average as no estimate data is available.
Unable to compare Valeo Pharma's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if Valeo Pharma is high growth as no earnings estimate data is available.
Unable to determine if Valeo Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Valeo Pharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Steven Saviuk, also known as Steve, CA, has been Executive Chairman of the Board of Directors at Ortho Regenerative Technologies Inc. since March 06, 2019. He serves as the Chairman and Chief Executive Officer of Manitex Capital Inc. and has been its President since 1995. Mr. Saviuk serves as Chief Executive Officer and Chairman of the Board of Intasys. He served as Chief Executive Officer at Ortho Regenerative Technologies Inc. Mr. Saviuk Co-founded Valeo Pharma Inc. in 2003 and has been its Chief Executive Officer and President since 2003 and also serves as its Director. He has been Chief Financial Officer of Cabia Goldhills, Inc. since 26, 2011. He serves as the Chairman of Chevalier Resources Inc. He served as the Chairman of Gee-Ten Ventures Inc. He served as the Chairman of Cabia Goldhills Inc. and has been its Director since October 26, 2011. He served as an Executive Chairman of Ortho Regenerative Technologies Inc. since February 5, 2015 until October 18, 2016 and served as its Interim President until November 26, 2015. Mr. Saviuk has been a Director of TECE, Inc. since October 2000 and Manitex Capital, Inc. since March 1995. He has been a Director at Earth Alive Clean Technologies Inc. since April 25, 2018. He has been Non-Independent Director of Ortho Regenerative Technologies Inc. since February 5, 2015. He serves as a Director of Lumenon Innovative Lightwave Technology, Inc. Mr. Saviuk served as a Director of Pinetree Capital Corp., since 2000 and Pinetree Capital Ltd. since March 2000. He served as a Director of Gee-Ten Ventures Inc., since 2010. He served as a Director of NSI Global Inc. Mr. Saviuk is a Chartered Accountant. Mr. Saviuk graduated from Concordia University (B.Comm).
Steve's compensation has increased whilst company is loss making.
Steve's remuneration is about average for companies of similar size in Canada.
Senior VP & CFO
Vice President of Operations
Senior VP & Chief Commercial Officer
Director of Communications & Investor Relations
VP of Legal Affairs & Corporate Secretary
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Valeo Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Valeo Pharma individual insiders in the past 3 months.
CNSX:VPH Historical Debt, July 19th 2019 A Look At Valeo Pharma's Liabilities The latest balance sheet data shows that Valeo Pharma had liabilities of CA$5.03m due within a year, and liabilities of CA$306.0k falling due after that. … Because it carries more debt than cash, we think it's worth watching Valeo Pharma's balance sheet over time. … When we look at that and recall the liabilities on its balance sheet, relative to cash, it seems unwise to us for the company to have any debt.
Valeo Pharma Inc. acquires and markets specialty products, and markets and distributes third-party pharmaceutical products. Its product portfolio includes Synacthen, a neurology therapeutic for the treatment of severe multiple sclerosis and gout; M-Eslon, an extended release morphine sulphate used for pain management; and M-Ediat, an immediate release morphine sulphate used for pain management. The company also offers Utrogestan, a micronized progesterone indicated for luteal phase support during in vitro fertilization cycles; and Onstryv, a safinamide tablet used to treat idiopathic Parkinson’s disease. In addition, it develops Ethacrynate Sodium, a loop diuretic used to treat high blood pressure, as well as the swelling caused by diseases, such as congestive heart failure, liver failure, and kidney failure. The company was founded in 2003 and is headquartered in Kirkland, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.